Floatz logo

zsp1602

Basal Cell Carcinoma

Guangdong Zhongsheng Pharmaceutical Co., Ltd.Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Basal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Genentech, Inc.
Phase 2BB
Multiple Vitamins Injection
Women's College Hospital
Phase 3BB
Cetuximab
Fox Chase Cancer Center
Phase 1/2B
Gdc-0449
Genentech, Inc.
Phase 2B
Pembrolizumab
Memorial Sloan Kettering Cancer Center
Phase 1/2CCC

View all 32 →

Same molecule, other indications

zsp1602 is also rated in:

medulloblastomaDormant
CC
Indicative ·
43 / 100
View asset →
gastroesophageal junction adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
neuroendocrine neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →